Successful treatment of West Nile virus infection after approximately 3 weeks into the disease course
- PMID: 17316156
- DOI: 10.1592/phco.27.3.455
Successful treatment of West Nile virus infection after approximately 3 weeks into the disease course
Abstract
West Nile virus can cause a febrile illness that may progress to meningoencephalitis. The only available treatments are ribavirin (although it has had limited success in humans) and interferon alpha-2b. A small pilot study showed that starting treatment with interferon alpha-2b on days 1-4 of hospital admission may reduce disease severity and complications. We encountered an 83-year-old man with West Nile meningoencephalitis who began taking interferon alpha-2b 3 weeks after disease presentation. Although studies and reports indicate that treatment is less likely to provide a favorable response if administered after days 1-6 of the disease course, the patient experienced substantial beneficial effects from this treatment. This is the first case report, to our knowledge, that describes successful treatment with interferon alpha-2b after several weeks of West Nile virus infection. Further studies are warranted to more fully understand the value of interferon alpha-2b in treating West Nile meningoencephalitis.
Similar articles
-
Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro.Emerg Infect Dis. 2002 Jan;8(1):107-8. doi: 10.3201/eid0801.010252. Emerg Infect Dis. 2002. PMID: 11749765 Free PMC article. No abstract available.
-
Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models.Antivir Chem Chemother. 2004 Mar;15(2):101-9. doi: 10.1177/095632020401500202. Antivir Chem Chemother. 2004. PMID: 15185728
-
Failure of interferon alpha-2b in a patient with West Nile virus meningoencephalitis and acute flaccid paralysis.Scand J Infect Dis. 2005;37(11-12):944-6. doi: 10.1080/00365540500262690. Scand J Infect Dis. 2005. PMID: 16308241 Review.
-
Calgary experience with West Nile virus neurological syndrome during the late summer of 2003.Can J Neurol Sci. 2004 May;31(2):194-203. doi: 10.1017/s031716710005383x. Can J Neurol Sci. 2004. PMID: 15198443
-
Development of effective therapies against West Nile virus infection.Expert Rev Anti Infect Ther. 2005 Dec;3(6):931-44. doi: 10.1586/14787210.3.6.931. Expert Rev Anti Infect Ther. 2005. PMID: 16307506 Review.
Cited by
-
A review of the mosquito-borne flaviviruses: Dengue virus and West Nile virus in Southern Africa.Virusdisease. 2025 Mar;36(1):1-11. doi: 10.1007/s13337-025-00917-x. Epub 2025 Apr 10. Virusdisease. 2025. PMID: 40290767 Free PMC article. Review.
-
Progress on the development of therapeutics against West Nile virus.Antiviral Res. 2009 Sep;83(3):214-27. doi: 10.1016/j.antiviral.2009.05.006. Epub 2009 Jun 6. Antiviral Res. 2009. PMID: 19501622 Free PMC article. Review.
-
A review of the epidemiological and clinical aspects of West Nile virus.Int J Gen Med. 2014 Apr 11;7:193-203. doi: 10.2147/IJGM.S59902. eCollection 2014. Int J Gen Med. 2014. PMID: 24748813 Free PMC article. Review.
-
Equine Immunoglobulin and Equine Neutralizing F(ab')₂ Protect Mice from West Nile Virus Infection.Viruses. 2016 Dec 18;8(12):332. doi: 10.3390/v8120332. Viruses. 2016. PMID: 27999340 Free PMC article.
-
Neurovirulence of Usutu virus in human fetal organotypic brain slice cultures partially resembles Zika and West Nile virus.Sci Rep. 2024 Aug 29;14(1):20095. doi: 10.1038/s41598-024-71050-w. Sci Rep. 2024. PMID: 39209987 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical